Specific gasdermin D inhibitors are in preclinical development, but disulfiram, a drug that has been FDA approved since 1951, was recently shown to inhibit gasdermin D in macrophages and to increase survival after experimental sepsis in mice (32, 33). Here, GSDMD is linked to Sepsis.